Clofazimine has shown effectiveness in the treatment of leprosy for many years. The World Health Organization and the National Hansen's Disease Program consider clofazamine to be standard therapy for treatment of multibacillary leprosy. In recent years, the availability of the drug has become limited and is currently available only under a research protocol and is considered "investigational." Use of Clofazamine in patients presenting with lepromatous leprosy is necessary for patients exhibiting nerve involvement or lesions resistant to other therapies. This drug will be used prospectively for patients who require treatment of leprosy as deemed appropriate by a Kaiser Permanente Southern California physician.
Treatment protocol objective is to treat patients with clofazamine who meet inclusion criteria stated above.
Study Type
EXPANDED_ACCESS
clofazamine 50mg po qday (duration varies according to physician)
Kaiser Permanente
Irvine, California, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.